Myriad Genetics Inc
$ 4.57
-2.56%
05 Jun - close price
- Market Cap 436,351,000 USD
- Current Price $ 4.57
- High / Low $ 4.72 / 4.53
- Stock P/E N/A
- Book Value 3.57
- EPS -4.31
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.24 %
- 52 Week High 8.59
- 52 Week Low 3.53
About
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$6.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-23 | 2025-11-03 | 2025-08-05 | 2025-05-06 | 2025-02-24 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-03 |
| Reported EPS | -0.09 | 0.04 | -0.29 | 0.05 | -0.03 | 0.03 | 0.06 | 0.05 | -0.01 | 0.04 | -0.03 | -0.08 |
| Estimated EPS | -0.07 | -0.0172 | -0.21 | -0.01 | -0.05 | 0.0303 | 0.02 | -0.01 | -0.11 | 0.01 | -0.08 | -0.09 |
| Surprise | -0.02 | 0.0572 | -0.08 | 0.06 | 0.02 | -0.0003 | 0.04 | 0.06 | 0.1 | 0.03 | 0.05 | 0.01 |
| Surprise Percentage | -28.5714% | 332.5581% | -38.0952% | 600% | 40% | -0.9901% | 200% | 600% | 90.9091% | 300% | 62.5% | 11.1111% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.06 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.75 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYGN
2026-06-05 20:38:43
Myriad Genetics director Colleen F. Reitan was granted 59,701 restricted stock units (RSUs) under the company's 2026 Employee, Director and Consultant Equity Incentive Plan. This equity award, which is compensation-related rather than a stock purchase, increases her direct holdings to 152,030 shares. The RSUs will vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.
2026-06-05 20:38:43
Myriad Genetics (MYGN) director Paul Bisaro has been granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Employee, Director and Consultant Equity Incentive Plan. These RSUs, which have no purchase price, will vest on the earlier of one year from the grant date or the next annual stockholder meeting. Following this grant, Bisaro directly holds 157,142 shares of common stock, representing a standard equity compensation practice to align director interests with shareholders.
2026-06-05 20:38:43
Myriad Genetics (NASDAQ: MYGN) director Rashmi Kumar was granted 59,701 restricted stock units (RSUs) as an equity award, bringing her direct holdings to 186,889 shares. These RSUs were granted at no cash cost under the company's 2026 Employee, Director and Consultant Equity Incentive Plan and will vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting. Each RSU represents a contingent right to receive one share of common stock upon vesting.
2026-06-05 20:38:43
Myriad Genetics Inc. director S. Louise Phanstiel was granted 59,701 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan at no cash cost. These RSUs will vest upon the earlier of one year from the grant date or the next annual stockholders' meeting. Following this transaction, Phanstiel directly holds 341,652 shares of common stock.
2026-06-05 20:38:43
Myriad Genetics (MYGN) Director Heinrich Dreismann was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan. These RSUs, awarded at no cash cost, will vest upon the earlier of one year from the grant date or the next annual stockholder meeting. Following this grant, Dreismann directly holds 231,145 shares of Myriad Genetics common stock.
2026-06-05 04:38:43
Myriad Genetics (MYGN) shares have risen 7.1% since its last earnings report, outperforming the S&P 500. Despite missing Q1 earnings estimates with an adjusted loss of 9 cents per share and a revenue miss, the company's Cancer Care Continuum and Mental Health businesses showed growth. Myriad maintains its full-year 2026 revenue and gross margin guidance, with a Zacks Rank #2 (Buy) indicating an expectation of above-average returns.
